1. ALLA AKTIER
  2. NYHETER
  3. CHORDATE MEDICAL

Chordate Medical

Nyheter Chordate Medical Nyheter alla bolag
Affiliate
Courtagefri handel på Nordnet till sista juni 2027! Har du inget konto på Nordnet så är det verkligen läge att skaffa ett. Just nu får nya kunder courtagefri handel till sista juni 2027. Läs mer om erbjudandet och skapa ditt konto här
Erbjudandet gäller nya kunder och omfattar handel via Nordnets app eller hemsida i nordiska aktier, ETF:er, teckningsrätter och teckningsoptioner. För fullständiga villkor se nordnet.se/jubileum. Kom ihåg att investeringar alltid innebär en risk.

Chordate Medical Presents at The Global Forum by Biostock 2024

Chordate’s CEO Anders Weilandt will present Ozilia at Biostock’s Global Forum on May 29, 2024. This event is one of several this spring where Chordate is participating to increase awareness of Ozilia among various investor segments within the Life Science sector.

– This particular event focuses largely on companies that are preparing to enter markets outside the Nordic region, and this aligns well with Chordate. We have already achieved success in several of our key markets and are now ready for the next step, says Anders Weilandt, CEO of Chordate.

Biostock’s Global Forum is designed to connect Nordic growth companies with a global network of potential investors and partners, from USA, Europe, and Asia.

– Over the past few months, we have worked hard to introduce Ozilia to as many potential investors in Life Science as possible, and this is yet another opportunity for us.

Read more about The Global Forum

For more information, please contact:
Anders Weilandt, CEO
anders.weilandt@chordate.com
Cell: +46 733-874277

About Chordate
Chordate Medical Holding AB (publ) is a medical technology company that has developed, patented and CE-marked Ozilia® Migraine (formerly K.O.S), a neuromodulation and drug-free treatment technology for chronic migraine and chronic rhinitis. The treatment has clinically proven efficacy according to a recent study, and is marketed in selected markets in the EU and the Middle East. Chordate Medical is listed on Nasdaq First North Growth Market Stockholm (ticker: CMH). Read more at www.chordate.com

The company's Certified Adviser on Nasdaq First North Growth Market Stockholm is Vator Securities AB.

N.B. The English text is an in-house translation of the original Swedish text. Should there be any disparities between the Swedish and the English text, the Swedish text shall prevail.

Attachments
Chordate Medical Presents at The Global Forum by Biostock 2024

Datum 2024-05-27, kl 09:40
Källa MFN
Bifogade filer
Chordate Medical Presents at The Global Forum by Biostock 2024